Current Report Filing (8-k)
May 15 2023 - 9:15AM
Edgar (US Regulatory)
0001782107
false
0001782107
2023-05-15
2023-05-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 15, 2023
Blue
Water Biotech, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41294 |
|
83-2262816 |
(State or other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
201
E. Fifth Street, Suite 1900 Cincinnati, Ohio |
|
45202 |
(Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (513) 620-4101
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on Which
Registered |
Common
Stock, par value $0.00001 per share |
|
BWV |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
7.01 Regulation FD Disclosure.
As
previously announced on May 10, 2023, the management of Blue Water Biotech, Inc., a Delaware corporation (the “Company”),
will present at the JMP Securities Life Sciences Conference at the New York Hilton Midtown on Monday, May 15, 2023 (the “JMP Conference”).
The Company’s presentation, which was originally scheduled for 3:30 p.m. EDT, has been moved to 11:00 a.m. EDT. In addition, the
form of the slide presentation the Company intends to use at the JMP Conference (the “Presentation”) is attached hereto as
Exhibit 99.1 and is being furnished herewith.
The
information in this Item 7.01 of this Current Report on Form 8-K (this “Current Report”) and the Presentation being furnished
herewith shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained
in this Item 7.01 and in the Presentation attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into
any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Blue Water Biotech, Inc. |
|
|
Date: May 15, 2023 |
/s/
Joseph Hernandez |
|
Joseph Hernandez
Chief Executive Officer |
2
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Jul 2023 to Jul 2024